VIDEO: Screening may become an option in the future for ILD in rheumatoid arthritis

ByJeffrey A. Sparks, MD, MMSc

ByMarley V. Ghizzone

Fact checked byShenaz Bagha

WASHINGTON — Healio spoke with Jeffrey A. Sparks, MD, MMSc, about baseline results from the SAIL-RA study, which assesses which patients with rheumatoid arthritis may be at risk for developing interstitial lung disease.

The data were presented at ACR Convergence 2024.

“I think this is going to be a really rich dataset in the future and it’s getting very close to being able to screen and find ILD early within rheumatoid arthritis,” said Sparks, an associate professor of medicine at Harvard Medical School and an associate program director of the Rheumatology Fellowship, director of Immuno-Oncology and Autoimmunity and director of the Joint Biology Consortium Human Biosamples Core at Brigham and Women’s Hospital.

Reference:

McDermott G, et al. Abstract #0802. Presented at: ACR Convergence 2024; Nov. 14-19, 2024; Washington, D.C.

Published by:

Sources/Disclosures

Collapse

Source:

Healio Interviews

Disclosures: Sparks reports receiving research support from Boehringer Ingelheim, Bristol Myers Squibb, Johnson & Johnson, and Sonoma Biotherapeutics; and serving as a consultant for AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Fresenius Kabi, Gilead Sciences, Inova Diagnostics, Johnson & Johnson, Merck, MustangBio, Novartis, Optum, Pfizer, ReCor, Sana, Sobi and UCB.

Discoveries in Rheumatoid Arthritis

Read more

VIDEO: Screening may become an option in the future for ILD in rheumatoid arthritis

Reference:

Related Content